ACG has been deeply involved with this matter since the very inception of the concern, working on two fronts.
On one side, the company has invested in the development of TiO2-free alternatives to support customer needs.
On the other, ACG has played a key role in educating the global pharmaceutical community about the scientific possibilities and limitations in addressing the challenge.
ACG is proud to have actively co-operated with the IQ Consortium, comprising 21 multinational pharmaceutical companies, in the creation of a robust database on the potential impact of a ban on TiO₂ in medicines.
This scientific body of evidence played a vital role in informing the European Commission’s decision-making process.
“This is a wise and pragmatic decision for the pharmaceutical sector,” said Dr Subhashis Chakraborty, General Manager, Head, Global Product Management at ACG Capsules.
“And as the ongoing ban remains in place for the nutraceutical industry, we remain fully committed to supporting through innovative TiO₂-free capsule solutions.”
Talking exclusively to NBR, Dr Subhashis Chakraborty (pictured) added: When the regulation on TiO₂ was first announced, it created significant uncertainty across the industry.
ACG responded swiftly and responsibly, taking the time to understand the challenge in depth. Rather than taking advantage of the situation, we chose to proactively share the technical limitations and complexities associated with finding viable TiO₂-free alternatives.
We made it very clear to our customers that an exact replacement for TiO₂, particularly to achieve white colour options, would not be possible with the current material science.
This helped to set realistic expectations and prevent unnecessary reformulation risks.
Our transparent communication enabled pharmaceutical companies, including the IQ Consortium, to make informed and strategic decisions, rather than operating in the dark.
In doing so, we represented ourselves not only as market leaders but also as thought leaders, guiding the industry with expertise and insight, rather than simply responding to regulatory changes.
In addition, while the regulatory changes originated in Europe, ACG also emphasised the broader global implications, especially for multinational corporations.
We advised that organisations with global operations should remain aligned and proactively plan for potential ripple effects beyond the EU.
As part of our commitment to supporting the industry, ACG has hosted multiple global knowledge-sharing sessions, including webinars, technical roundtables and direct consultations.
These efforts continue to guide and educate the pharmaceutical community on both the regulatory landscape and the path forward for TiO₂-free innovations.
In addition, if you want to hear more from Dr Subhashis Chakraborty, then check out our recent webinar – in partnership with Manufacturing Chemist — which looks at how HPMC is changing the game in oral solid dosage forms such as capsules.